Assignee
ONCOIMMUNE INC
US·9 granted patents·11 pending applications·17 citations·filing 2013–2021
Top patents by PatentIndex Score
20 records- 0195US10618960B2Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereofONCOIMMUNE INC·Filed 2016·Granted Apr 14, 2020·12 cites·14 claims
- 0282US10793617B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2018·Granted Oct 6, 2020·1 cites·14 claims
- 0382US9611309B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2014·Granted Apr 4, 2017·2 cites·17 claims
- 0481US8895022B2Methods of use of soluble CD24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2013·Granted Nov 25, 2014·2 cites·9 claims
- 0572US2020399345A1Methods of use of soluble cd24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 0671US2021161991A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 0769US2020147167A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 0865US2019255140A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2019·Application pending·0 cites
- 0963US9877998B2Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2017·Granted Jan 30, 2018·0 cites·6 claims
- 1062US2018177841A1Uses of hypoxia-inducible factor inhibitorsONCOIMMUNE INC·Filed 2017·Application pending·0 cites
- 1162US2017233453A1Methods of use of soluble cd24 for therapy of rheumatoid arthritisONCOIMMUNE INC·Filed 2017·Application pending·0 cites
- 1259US11571461B2Methods of use of soluble CD24 for treating lupus nephritisONCOIMMUNE INC·Filed 2018·Granted Feb 7, 2023·0 cites·11 claims
- 1358US2021162006A1Use of CD24 Proteins for Treating Leptin-Deficient ConditionsONCOIMMUNE INC·Filed 2020·Application pending·0 cites
- 1457US10799558B2Use of CD24 proteins for treating leptin-deficient conditionsONCOIMMUNE INC·Filed 2017·Granted Oct 13, 2020·0 cites·19 claims
- 1554US11911441B2Methods of use of CD24 for the prevention and treatment of leukemia relapseONCOIMMUNE INC·Filed 2019·Granted Feb 27, 2024·0 cites·16 claims
- 1652US2023108492A1Methods of use of soluble cd24 for treating viral pneumoniaONCOIMMUNE INC·Filed 2021·Application pending·0 cites
- 1750US2021046154A1Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)ONCOIMMUNE INC·Filed 2019·Application pending·0 cites
- 1850US2020181235A1Methods of use of soluble cd24 for neuroprotection and remyelinationONCOIMMUNE INC·Filed 2018·Application pending·0 cites
- 1948US2023103352A1Methods of use of soluble cd24 for treating sars-cov-2 infectionONCOIMMUNE INC·Filed 2021·Application pending·0 cites
- 2046US11547741B2Methods of use of soluble CD24 for treating immune related adverse events in cancer therapiesONCOIMMUNE INC·Filed 2018·Granted Jan 10, 2023·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when ONCOIMMUNE INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →